ImmuCell Corporation Investor Presentation August 2025 (Nasdaq: ICCC) 2 Table of Contents | 1) | Company Overview and Strategic Opportunity..…….……..…………………………………………………….….… 4-27 | | --- | --- | | 2) | Testimonials………………………………………………………………….……..…….…………………………………….……….…28-32 | | 3) | Financial Review(1).………………..….……..……………………………..……………………………………………..… 33-39 | | 4) | Other Information..……………...………...………………………………………….……………………………...……….…….40-52 | (1)Detailed financial reports, summary press releases and conference ...

PORTLAND, Maine, June 25, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has commenced a search for a successor in the position of President and CEO. “I turn 65 this fall and have told my fellow Directors that I would like to retire from full-time work by ear ...

Company Overview and Strategy - ImmuCell Corporation focuses on growth in First Defense product line sales and aims to revolutionize subclinical mastitis treatment with Re-Tain[10] - The company addresses the $2 billion annual economic harm to the dairy industry caused by mastitis without traditional antibiotics, using Re-Tain (subject to FDA approval)[10, 53] - Three critical action items include growing First Defense sales, achieving FDA approval for Re-Tain, and proving market acceptance of Re-Tain with $10 million annual production capacity[18] - The company completed an investment to increase First Defense production capacity to over $30 million in annual sales value[29, 49] Product Lines and Market Opportunities - The U S market opportunity for calf-level products to prevent scours is approximately $31 1 million annually[32, 51] - The U S market opportunity for calf-level and dam-level vaccine products used to prevent scours is estimated at $81 8 million annually[32, 51] - Mastitis causes an estimated $2 billion in economic loss to the dairy industry each year[33, 52] Financial Performance - As of March 31, 2025, the company's cash and cash equivalents were $4 6 million, and total assets were $45 6 million[83] - For the three-month period ended March 31, 2025, product sales were $8 1 million, with a gross margin of 42%[87] - The company's total project cost for First Defense is estimated at $14 177 million, and for Re-Tain, it's $5 382 million[90]

Core Viewpoint - ImmuCell Corporation has appointed Timothy C. Fiori as Chief Financial Officer, bringing significant experience to the company during a crucial phase of its development [1][2][3]. Company Overview - ImmuCell Corporation focuses on developing, manufacturing, and marketing products that enhance the health and productivity of dairy and beef cattle [4]. - The company offers First Defense®, which provides Immediate Immunity™ to newborn calves, and is nearing the completion of Re-Tain®, a treatment for subclinical mastitis in dairy cows that avoids traditional antibiotic restrictions [4]. Leadership Changes - Timothy C. Fiori has approximately 24 years of finance and commercial operating experience from IDEXX Laboratories [2]. - Fiori expressed enthusiasm about joining ImmuCell and contributing to the company's growth, highlighting the potential of its product portfolio [3]. - Michael F. Brigham, President and CEO, emphasized that Fiori's experience will be instrumental in improving financial systems and operational efficiencies [3].